Diabetic Retinopathy
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy
Valo Health Suspends Development of OPL-0401, a ROCK Inhibitor for Diabetic Retinopathy, Following Phase 2 Study Results
Valo Health, OPL-0401, ROCK Inhibitor, Diabetic Retinopathy, Phase 2 Study, Clinical Trials, Drug Development
FDA Grants Approval for First Interchangeable Biosimilars to Regeneron’s Eylea
FDA, biosimilars, interchangeable, Regeneron, Eylea, approval, blockbuster, drug, treatment, eye diseases, macular degeneration, diabetic retinopathy, retinal vein occlusion